To Our Shareholders

Interim Report for the 97th Business Period

From April 1 to September 30, 2020

KANEKA CORPORATION
Message from the President

To our valued shareholders, Thank you for your continued support and interest in Kaneka Group. President and Representative Director Minoru Tanaka, who was appointed in April 2020, reviews the business performance for the first half, the forecast, and the new medium-term management plan.

Q How did you feel about your appointment as president in April?
A When I was approached about the appointment, the Company’s earnings were struggling, and my first thought was that I would be taking on a tremendous responsibility. At the same time, I felt a strong sense of mission—that I must do something to close the gap and realize the 2020 goals that we had laid out under the long-term management vision, “Declaration of Kaneka United for the future,” which we formulated when I was General Manager of the Corporate Planning Division. Partly because of the impact of the COVID-19 pandemic, my term has started in rough conditions, but I intend to contribute as best as I can as the culmination of my life in the Company.

Q Could you review the first half and give your forecast for the second half and onward?
A Global economic activity has been hit hard by the COVID-19 pandemic, giving rise to a rapid paradigm shift in society, along with a variety of changes in people’s values. The global economy rebounded from the serious downturn in the first quarter (April–June 2020; “1Q”) and showed increasingly strong signs of recovery in various industries in the second quarter (July–September 2020; “2Q”), primarily in China and the U.S. From October onward, the pace of recovery is expected to increase overall, despite some lingering uncertainty about factors such as the impact of a second wave of COVID-19 in Europe and the U.S. Under the current conditions, the Group’s first-half performance saw decreases in both sales and profits year on year, with net sales of ¥266.7 billion and operating income of ¥7.0 billion. However, the foundation business group (Vinyls and Chlor-Alkali, Performance Polymers (MOD), Performance Polymers (MS), Foam & Residential Techs, Performance Fibers, and Foods & Agris), which was heavily impacted by the COVID-19 crisis in 1Q, has steadily improved from 2Q onward, owing to progress on an improvement in production in step with the resumption of global economic activity. The Company now sees a clear path for the foundation business group to return to a trajectory for additional growth beyond COVID-19. The highly profitable leading-edge business group (E & I Technology, PV & Energy management, Medical, Pharma, Supplemental Nutrition, and Agricultural production support), which has an expanding range of growth opportunities amid the current paradigm shift, continues to achieve steady growth. As a result, we anticipate stronger momentum from October onward, shifting our performance from an improvement to a stage of resurgent growth. Looking ahead, the dramatic paradigm shift caused by the coronavirus shock, the Company is working to improve productivity and create new business value by applying a “select and concentrate” strategy to Research & Business (R&B) initiatives and by promoting digital transformation (DX) of back office departments and other areas. Meanwhile, the Company is working to implement rigorous cost rationalization, including operating expenses. The Company will work to accelerate the transformation of the business portfolio by striving to realize “Smart Work,” a Company-wide initiative to maximize productivity.

To our valued shareholders, Thank you for your continued support and interest in Kaneka Group.
Q A new medium-term management plan was announced in October. Could you give an overview of the plan?

A Under the new medium-term management plan, we will further accelerate the portfolio transformation. While striving to strengthen our corporate constitution amid COVID-19, we will prioritize allocation of management resources to leading-edge businesses such as E & I, PV, Medical, Pharma and the paradigm change, as well as new large-scale businesses will prioritize allocation of management resources to leading-edge businesses to create high added value. We will make leading-edge businesses a core pillar driving Kaneka’s business performance. Focusing on infectious diseases, in Pharma, we will further expand facilities at Kaneka Eurogentec S.A. (“KEGT”), where orders for COVID-19 vaccines and treatments are growing rapidly. In Medical business, we will increase the production capacity of our plant in Vietnam to meet robust demand that is globally growing, while aiming to expand the scope of our operations in areas that can help address COVID-19, such as testing and diagnostics and medical devices. As a result, we will greatly expand intervention business.

The COVID-19 pandemic is speeding up the sophistication of digital and telecommunications all at once. With social implementation of 5G, EVs, and CASE advancing, our goal in E & I is to grasp market trends and develop distinctive materials that contribute to the digital society and expand business in the polyimide products, optical film, optoelectronics fields.

In new large-scale businesses, especially PHBH, we need to accelerate social implementation, so we are working with global brand holders to develop applications. We plan to build a commercial production plant and hope to be able to announce it at the earliest possible time.

Meanwhile, in the foundation businesses, we will build a strong platform to support the management base. In Vinyls and Chlor-Alkali and Performance Polymers (MOD, MS), we will announce it at the earliest possible time.

And finally, regarding the interim dividend, we have decided on ¥50 per share. I thank you very much for your continued support.

Highlights of consolidated business performance

<table>
<thead>
<tr>
<th>(Billions of Yen)</th>
<th>94th FY2017</th>
<th>95th FY2018</th>
<th>96th FY2019</th>
<th>97th FY2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>360.1</td>
<td>364.9</td>
<td>370.9</td>
<td>377.0</td>
</tr>
<tr>
<td>Operating income</td>
<td>21.0</td>
<td>21.0</td>
<td>21.0</td>
<td>21.0</td>
</tr>
<tr>
<td>Net income</td>
<td>2.0</td>
<td>2.0</td>
<td>2.0</td>
<td>2.0</td>
</tr>
</tbody>
</table>

KANEKA
In the Performance Fibers business, demand for hair accessories and flame retardance materials for Africa and the U.S. slumped due to the COVID-19 impact in 1Q. But demand for hair accessories in Africa have been recovering every month since July. There have been delays in the recovery of demand for flame retardance materials and pile for apparel applications.

In the Foam & Residential Techs business, spreads were maintained for expanded polyurethane resin and extruded polystyrene foam boards despite sluggish domestic demand. Polyurethane foam products for automobiles, which had been falling behind, follow a recovery trend.

In the PV & Energy management business, sales of high-efficiency photovoltaic modules products for residences were firm due to an increase in the adoption rate.

In the E & I Technology business, in 2Q, the shipments of PIBEO products recorded an all-time high. This is because demand for smartphones and materials for tablets and laptop PCs was strong due to increasing remote work population in connection with the COVID-19 crisis. Sales increased for 5G products. New product development is also progressing steadily.

The Quality of Life Solutions Unit recorded lower sales and profits than previous year.

In the Medical business, the domestic and overseas markets both expanded. Cols for embalming of brain aneurysms, a new product, performed well. Sales of this new product began in the U.S. in September and have been contributing to earnings growth. Sales of a new blood purification system for treatment of arteriosclerosis (ASO) are scheduled for 2021.

In the Pharma business, earnings rose sharply year on year, due to factors such as the start of the supply of active pharmaceutical ingredients for Avigan® Tablet and Kaneka Eurogentec S.A.’s reagents for PCR tests. Kaneka Eurogentec S.A. has received a growing number of inquiries from major global pharmaceutical companies, beginning with expanded therapies for ovarian cancer. Kaneka Eurogentec S.A. is currently considering implementing the next phase of capacity increase at an early stage.
The current COVID-19 pandemic has created social issues not only for those infected, but also in terms of preventing infection among workers, such as frontline medical staff. Demand for ultra-thin gloves to prevent COVID-19 infection has been growing rapidly around the world, mainly for people working in medicine and food industries. In Japan, limited availability has caused prices to soar.

In this environment, the Company has continued to provide a stable supply of Paste PVC, which is a material for hygienic gloves. In this way, we are meeting expanding demand and contributing to infection prevention and hygiene countermeasures.

The Company aims to make optimal use of its diverse technologies to promote unique social applications in a wide range of fields. To this end, we have established an in-house Infection Research Team to promote R&D into infection countermeasures.

Kaneka is taking a wide range of measures to help solve the coronavirus crisis, including the PCR test kit, the PCR reagents, the manufacturing of a DNA vaccine intermediate, the supplying of active pharmaceutical ingredients for Avigan® Tablet.

Response to Urgent Global Measures to Prevent Infection

There is still no clear end in sight to the current COVID-19 pandemic. However, the Company has actively moved to supply PCR testing reagents and active pharmaceutical ingredients (APIs) for Avigan® Tablet since the virus started spreading. In August 2020, we participated in a manufacturing system for mass production of a DNA vaccine*1 being developed by AnGes, Inc. and Osaka University. Our Group company, Kaneka Eurogentec S.A., has received a contract for production of vaccine intermediates. Kaneka Eurogentec S.A. has high level cutting-edge technologies such as mRNA*2 and plasmid DNA*3 and continues to handle a surge of inquiries for contracted production of COVID-19 vaccine, the development of which has been accelerated by pharmaceutical companies and bioventures.

In addition, in October 2020, our domestic Group company, Kaneka Medix Corporation (Headquarters: City of Osaka; President: Shozo Ishizaka), started sales of an RT-q PCR kit (product name: KANEKA Direct RT-q PCR Kit “SARS-CoV-2”), able to detect COVID-19 within one hour to medical and testing institutions.

With this newly launched testing kit, pre-treatment is completed by heat treatment only, as there is no need to purify RNA*4 from the virus using samples taken from saliva or the top of the throat. Accordingly, the pretreatment that with conventional methods took around one hour is reduced to around 5 minutes, allowing the overall time needed for the PCR test to be greatly reduced to within an hour.

The Company implements ESG management and aims for the goal of “Wellness First” to make the world healthy. We have identified three areas in which we can contribute to solutions for global crises as “Environment/Energy,” “Food,” and “Wellness.”

Feature: KANEKA thinks “Wellness First”. Solutions to Three Crises

Kaneka will concentrate its technologies to provide solutions to global threats

The Company has identified three key areas where it can contribute to global crises: “Environment/Energy,” “Food,” and “Wellness.” In this feature, we pick up on the theme of Wellness to introduce a range of solutions for COVID-19.

Response to Urgent Global Measures to Prevent Infection

There is still no clear end in sight to the current COVID-19 pandemic. However, the Company has actively moved to supply PCR testing reagents and active pharmaceutical ingredients (APIs) for Avigan® Tablet since the virus started spreading. In August 2020, we participated in a manufacturing system for mass production of a DNA vaccine*1 being developed by AnGes, Inc. and Osaka University. Our Group company, Kaneka Eurogentec S.A., has received a contract for production of vaccine intermediates. Kaneka Eurogentec S.A. has high level cutting-edge technologies such as mRNA*2 and plasmid DNA*3 and continues to handle a surge of inquiries for contracted production of COVID-19 vaccine, the development of which has been accelerated by pharmaceutical companies and bioventures.

In addition, in October 2020, our domestic Group company, Kaneka Medix Corporation (Headquarters: City of Osaka; President: Shozo Ishizaka), started sales of an RT-q PCR kit (product name: KANEKA Direct RT-q PCR Kit “SARS-CoV-2”), able to detect COVID-19 within one hour to medical and testing institutions.

With this newly launched testing kit, pre-treatment is completed by heat treatment only, as there is no need to purify RNA*4 from the virus using samples taken from saliva or the top of the throat. Accordingly, the pretreatment that with conventional methods took around one hour is reduced to around 5 minutes, allowing the overall time needed for the PCR test to be greatly reduced to within an hour.

The Company implements ESG management and aims for the goal of “Wellness First” to make the world healthy. We have identified three areas in which we can contribute to solutions for global crises as “Environment/Energy,” “Food,” and “Wellness.”

Response to Urgent Global Measures to Prevent Infection

There is still no clear end in sight to the current COVID-19 pandemic. However, the Company has actively moved to supply PCR testing reagents and active pharmaceutical ingredients (APIs) for Avigan® Tablet since the virus started spreading. In August 2020, we participated in a manufacturing system for mass production of a DNA vaccine*1 being developed by AnGes, Inc. and Osaka University. Our Group company, Kaneka Eurogentec S.A., has received a contract for production of vaccine intermediates. Kaneka Eurogentec S.A. has high level cutting-edge technologies such as mRNA*2 and plasmid DNA*3 and continues to handle a surge of inquiries for contracted production of COVID-19 vaccine, the development of which has been accelerated by pharmaceutical companies and bioventures.

In addition, in October 2020, our domestic Group company, Kaneka Medix Corporation (Headquarters: City of Osaka; President: Shozo Ishizaka), started sales of an RT-q PCR kit (product name: KANEKA Direct RT-q PCR Kit “SARS-CoV-2”), able to detect COVID-19 within one hour to medical and testing institutions.

With this newly launched testing kit, pre-treatment is completed by heat treatment only, as there is no need to purify RNA*4 from the virus using samples taken from saliva or the top of the throat. Accordingly, the pretreatment that with conventional methods took around one hour is reduced to around 5 minutes, allowing the overall time needed for the PCR test to be greatly reduced to within an hour.

The Company implements ESG management and aims for the goal of “Wellness First” to make the world healthy. We have identified three areas in which we can contribute to solutions for global crises as “Environment/Energy,” “Food,” and “Wellness.”

Response to Urgent Global Measures to Prevent Infection

There is still no clear end in sight to the current COVID-19 pandemic. However, the Company has actively moved to supply PCR testing reagents and active pharmaceutical ingredients (APIs) for Avigan® Tablet since the virus started spreading. In August 2020, we participated in a manufacturing system for mass production of a DNA vaccine*1 being developed by AnGes, Inc. and Osaka University. Our Group company, Kaneka Eurogentec S.A., has received a contract for production of vaccine intermediates. Kaneka Eurogentec S.A. has high level cutting-edge technologies such as mRNA*2 and plasmid DNA*3 and continues to handle a surge of inquiries for contracted production of COVID-19 vaccine, the development of which has been accelerated by pharmaceutical companies and bioventures.

In addition, in October 2020, our domestic Group company, Kaneka Medix Corporation (Headquarters: City of Osaka; President: Shozo Ishizaka), started sales of an RT-q PCR kit (product name: KANEKA Direct RT-q PCR Kit “SARS-CoV-2”), able to detect COVID-19 within one hour to medical and testing institutions.

With this newly launched testing kit, pre-treatment is completed by heat treatment only, as there is no need to purify RNA*4 from the virus using samples taken from saliva or the top of the throat. Accordingly, the pretreatment that with conventional methods took around one hour is reduced to around 5 minutes, allowing the overall time needed for the PCR test to be greatly reduced to within an hour.

The Company implements ESG management and aims for the goal of “Wellness First” to make the world healthy. We have identified three areas in which we can contribute to solutions for global crises as “Environment/Energy,” “Food,” and “Wellness.”

The Company aims to make optimal use of its diverse technologies to promote unique social applications in a wide range of fields. To this end, we have established an in-house Infection Research Team to promote R&D into infection countermeasures.

Kaneka is taking a wide range of measures to help solve the coronavirus crisis, including the PCR test kit, the PCR reagents, the manufacturing of a DNA vaccine intermediate, the supplying of active pharmaceutical ingredients for Avigan® Tablet.

Looking ahead, the Company will bring together its various technologies to assist patients and relevant staff, providing various solutions such as innovative treatments that allow people to spend their healthy, safe and secure lives. In doing so, we will make the entire world healthier.

Sustainable Solutions for an Evolving World.

The Company aims to make optimal use of its diverse technologies to promote unique social applications in a wide range of fields. To this end, we have established an in-house Infection Research Team to promote R&D into infection countermeasures.

Kaneka is taking a wide range of measures to help solve the coronavirus crisis, including the PCR test kit, the PCR reagents, the manufacturing of a DNA vaccine intermediate, the supplying of active pharmaceutical ingredients for Avigan® Tablet.

Looking ahead, the Company will bring together its various technologies to assist patients and relevant staff, providing various solutions such as innovative treatments that allow people to spend their healthy, safe and secure lives. In doing so, we will make the entire world healthier.

Sustainable Solutions for an Evolving World.

The Company aims to make optimal use of its diverse technologies to promote unique social applications in a wide range of fields. To this end, we have established an in-house Infection Research Team to promote R&D into infection countermeasures.

Kaneka is taking a wide range of measures to help solve the coronavirus crisis, including the PCR test kit, the PCR reagents, the manufacturing of a DNA vaccine intermediate, the supplying of active pharmaceutical ingredients for Avigan® Tablet. Looking ahead, the Company will bring together its various technologies to assist patients and relevant staff, providing various solutions such as innovative treatments that allow people to spend their healthy, safe and secure lives. In doing so, we will make the entire world healthier.

Sustainable Solutions for an Evolving World.

The Company aims to make optimal use of its diverse technologies to promote unique social applications in a wide range of fields. To this end, we have established an in-house Infection Research Team to promote R&D into infection countermeasures.

Kaneka is taking a wide range of measures to help solve the coronavirus crisis, including the PCR test kit, the PCR reagents, the manufacturing of a DNA vaccine intermediate, the supplying of active pharmaceutical ingredients for Avigan® Tablet. Looking ahead, the Company will bring together its various technologies to assist patients and relevant staff, providing various solutions such as innovative treatments that allow people to spend their healthy, safe and secure lives. In doing so, we will make the entire world healthier.

Sustainable Solutions for an Evolving World.
Development of dairy products

The Company entered the dairy product business in 2018. We have been selling and extending our range of dairy products, including the popular “Milk for Bread Lovers” series, as well as “Belgian Yogurt Pur Natu,” a collaboration product made with our technical tie-up partner Pur Natur Invest BVBA of Belgium, and “Pur Natur Fermented Butter.” These products have earned a high reputation in the market and we are aiming to expand our sales outlets such as convenience stores and supermarkets in addition to our bakery store channel. In addition, in the near future we plan to launch a new milk tea product in the “Milk for Bread Lovers” series, and a health-conscious yogurt with the active form of coenzyme Q10.

Since October 2020, we have set up a link to our online shop (https://www.kane.co.jp/online-shop/) on our official website. Please try it.

Establishment of an Organic Dairy Farming Company

In June 2020, together with Betsukai Milk World Co., Ltd. (Location: Betsukai-cho, Notsuke District, Hokkaido; President: Sadayuki Nakayama), we established Betsukai Wellness Farm Co., Ltd., a company that will manufacture and sell organic raw milk*. As an exclusively organic farm, Betsukai Wellness Farm will engage in highly productive organic dairy farming. Betsukai Wellness Farm’s organic farm will go into operation in April 2021, and by 2022 we are aiming to acquire the organic JAS certification** in regard to raw milk. The raw milk on this farm will be fully purchased by Kaneka and will be used to expand our product line up to such organic dairy products as milk, butter, and in particular yoghurt.

Japan’s dairy farming industry is currently under harsh conditions. Our philosophy is to work with dairy farmers to consider attractive dairy farming and promote sustainable and circular dairy farming that takes into consideration people, cows, and the environment. Aiming to Combine Delicious Flavors with Health

Production Capacity in Vietnam Increased

In Japan and Vietnam, Kaneka manufactures medical catheters such as endovascular treatment catheters for cardiovascular, peripheral vascular, and cerebrovascular disease, gastroenterology intervention for the treatment of gastrointestinal cancer*** and electrode catheter for irregular pulse test. In order to meet strong and growing global demand, Kaneka decided in June 2020 to increase the medical catheter production capacity of Group subsidiary Kaneka Medical Vietnam Co., Ltd. (Headquarters: Binh Duong, Vietnam; President: Toshiyuki Morii). It will build a new plant adjacent to its existing plant, roughly tripling its production capacity. The new plant is scheduled to go into operation from January 2022.

Development of a new Adsorption Type Blood Purification Device

The Company has developed a new adsorption type blood purification device for treating a severe form of arteriosclerosis obliterans (ASO) with ulcers** (Product name: RheocarnaTM) and acquired approval for its manufacture and sales in August 2020 with a view to starting sales in spring of 2021.

Due to the growing aging population and increasing diabetes and chronic renal failure, which lead to the most severe form, ASO patients are predicted to increase. The adsorption type blood purification device developed by Kaneka works by selectively removing substances causing ASO symptoms and returns purified blood to the body. This is now possible thanks to the development of novel cellulose beads that adsorb the substances.

Looking ahead, Kaneka will provide solutions that contributed to minimally invasive treatments and blood purification treatments, thereby helping to improve patients’ quality of life.
Facilities

Kaneka Corporation has signed an agreement with Japan Tobacco Inc. (“JT”) to acquire JT’s assets related to plant biotechnology in August 2020. The objective of this asset acquisition is to significantly accelerate research and development of crop genome editing and to innovate conventional crop breeding, by taking advantage of Kaneka’s core technology in planta Genome Editing Technology™(iPB method), which is highly efficient and applicable to a wide range of commercial crop varieties, and JT’s state-of-the-art research facilities, global network with agro-industry and cutting-edge gene delivery technology. Hereafter, we will accelerate research and development in a new organization, strengthen license business of gene engineering technology to seed companies, and conduct research and development** of crop varieties with beneficial agronomic traits like functionality and high yields under contract with seed companies. Our future targets include seed business of genome-edited crop varieties, which is expected to grow rapidly. Guided by its principle of “KANEKA Thinks Wellness First,” Kaneka will utilize open innovation to accelerate provision of solutions of various global food problems, such as safe, secure, stable food supply.

Kaneka’s unique plant breeding technology: iPB method

1 Breeding technology to introduce beneficial traits such as disease resistance into plants (tissue culture technology, gene delivery technology, etc.)
2 Technology for rapid crop breeding that enables gene modification without integrating the gene cassettes of genome editing technology into the plant chromosomes.
3 Developing genome editing seed for requests from customers.

Topics

Supporting Agricultural Production by Accelerating Research and Development into Crop Breeding Based on Genome Editing

<table>
<thead>
<tr>
<th>Genome editing tool</th>
<th>Meristem</th>
<th>Useful cultivars</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dramatically accelerate crop breeding</td>
<td>Tissue culture process is no longer necessary</td>
<td>Advanced application to genome editing</td>
</tr>
<tr>
<td>Gamering seed</td>
<td>High-precision gene modification</td>
<td></td>
</tr>
</tbody>
</table>

JT’s business assets related to plant biotechnology

- Net cash provided by operating activities was ¥28.2 billion, mainly due to income before income taxes and depreciation and amortization.
- Net cash used in investing activities amounted to ¥22.8 billion, mainly due to the purchase of property, plant and equipment.
- Net cash used in financing activities was ¥3.0 billion, mainly owing to cash dividends paid.
- As a result, cash and cash equivalents as of September 30, 2020 totaled ¥39.9 billion.

Consolidated Financial Statements

<table>
<thead>
<tr>
<th>Accounts title</th>
<th>97th (As of September 30, 2020)</th>
<th>96th (As of March 31, 2020)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current assets</td>
<td>292.0 306.9</td>
<td></td>
</tr>
<tr>
<td>Total assets</td>
<td>644.3 653.3</td>
<td></td>
</tr>
<tr>
<td>Current liabilities</td>
<td>206.1 211.6</td>
<td></td>
</tr>
<tr>
<td>Noncurrent liabilities</td>
<td>81.0 87.6</td>
<td></td>
</tr>
<tr>
<td>Total liabilities</td>
<td>287.1 299.2</td>
<td></td>
</tr>
<tr>
<td>Shareholders’ equity</td>
<td>332.1 332.7</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>25.1 21.4</td>
<td></td>
</tr>
<tr>
<td>Total net assets</td>
<td>357.2 354.1</td>
<td></td>
</tr>
<tr>
<td>Total liabilities and net assets</td>
<td>644.3 653.3</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Accounts title</th>
<th>97th (From April 1, 2020 to September 30, 2020)</th>
<th>96th (From April 1, 2019 to September 30, 2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>266.7 299.6</td>
<td>301.8 312.3</td>
</tr>
<tr>
<td>Operating income</td>
<td>7.0 12.8</td>
<td>4.0 9.7</td>
</tr>
<tr>
<td>Ordinary income</td>
<td>9.9 9.1</td>
<td>2.5 6.0</td>
</tr>
<tr>
<td>Net income attributable to owners of parent</td>
<td>2.5 6.0</td>
<td></td>
</tr>
</tbody>
</table>
Corporate Data

<table>
<thead>
<tr>
<th>Name</th>
<th>KANEKA CORPORATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tokyo Head Office</td>
<td>1-12-32, Akasaka, Minato-ku, Tokyo 107-6028, Japan</td>
</tr>
<tr>
<td>TEL.</td>
<td>+81-3-5574-8000</td>
</tr>
<tr>
<td>Osaka Head Office</td>
<td>2-3-18, Nakanoshima, Kita-ku, Osaka 530-8288, Japan</td>
</tr>
<tr>
<td>TEL.</td>
<td>+81-6-6226-5050</td>
</tr>
</tbody>
</table>

Date of Establishment: September 1, 1949
Paid-In Capital: 33,046 million yen

Website: [https://www.kaneka.co.jp/en/](https://www.kaneka.co.jp/en/)

Stock Information

- Total number of authorized shares: 150,000,000 shares
- Number of Shares Issued and Outstanding: 68,000,000 shares
- Number of shareholders: 22,976 shareholders
- Average number of shares per shareholder: 2,960 shares

Major Shareholders

- The Master Trust Bank of Japan, Ltd. (Trust Account): 4,444 shares, 6.81%
- Custody Bank of Japan, Ltd. (Trust Account): 3,986 shares, 6.11%
- Nippon Life Insurance Company: 3,114 shares, 4.77%
- Sumitomo Mitsui Banking Corporation: 3,091 shares, 4.74%
- Meiji Yasuda Life Insurance Company: 2,825 shares, 4.33%
- Custody Bank of Japan, Ltd. (Trust Account No.4): 2,673 shares, 4.10%
- MFG Bank, Ltd.: 2,306 shares, 3.54%
- Mitsui Sumitomo Insurance Company, Limited: 2,104 shares, 3.23%
- BNYMANS AGENT/CLIENTS LUX UCITS NON TREATY 1: 1,470 shares, 2.25%
- Kaneka Business Partner Shareholding Association: 1,154 shares, 1.77%

Notes:
1. The numbers of Share Units Owned are rounded down to thousands of shares.
2. For shares registered in special accounts, please inquire to the special account managing institution.

Shareholder Composition

- Financial institution: 35,554 shares (52.3%)
- Foreign companies: 13,780 shares (20.3%)
- Individuals and others: 12,400 shares (18.2%)
- Other companies: 5,257 shares (7.9%)
- Financial institutions firms: 906 shares (1.3%)

Notes:
1. The numbers of Share Units Owned are rounded down to thousands of shares.
2. The Percentage of Total Shares Issued is calculated by using deducting number of treasury shares from Number of Shares Issued and Outstanding and rounded to two decimal places.
3. The Percentage is calculated by using the above list, the Company maintains 2,762 thousand shares of treasury stock.

IR Information

The website contains information such as management policy, business performance and financial information, IR materials, and stock information.

Cover art illustration: Aiso Sora
- Title: Sora
- Creation date: 2013

Kaneka’s Website

Kaneka’s website provides clear, easy to use information to stakeholders such as shareholders and investors. We will continue to enhance the content of the website and to provide timely, appropriate disclosure.